Summary & Overview
HCPCS J3357: Ustekinumab, Subcutaneous Injection, 1 mg
HCPCS Level II code J3357 designates ustekinumab measured as 1 mg for subcutaneous injection. Ustekinumab is a monoclonal antibody used in several immune-mediated conditions; accurately reporting the drug unit is essential for claims processing, utilization tracking, and payment determination across outpatient and ambulatory care settings. Nationally, biologic drug codes like J3357 are central to specialty drug billing and oversight due to high unit costs and dosing variability.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the clinical context for ustekinumab, typical sites of service for subcutaneous administration, and the role of the J3357 code in billing. The publication also summarizes benchmarks and billing considerations relevant to payers, common modifier usage (where available), and how this HCPCS Level II code interacts with claims workflows.
What readers will learn: how J3357 is used on medical claims, the clinical setting and service type tied to the code, payer coverage landscape, and where to look for policy updates or coding guidance. Data not available in the input: detailed payer-specific reimbursement rates, associated ICD-10 diagnoses, related codes, service line specifics, and provider taxonomies.
Billing Code Overview
HCPCS Level II code J3357 describes ustekinumab, for subcutaneous injection, 1 mg. This code represents the medication unit of ustekinumab supplied for subcutaneous administration and is used to report the drug quantity on medical claims.
Service type: Subcutaneous biologic drug administration
Typical site of service: Outpatient clinic, physician office, infusion or injection center, or other ambulatory care settings where subcutaneous biologic injections are administered.
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with moderate to severe plaque psoriasis, psoriatic arthritis, or Crohn disease who requires maintenance or induction biologic therapy with subcutaneous ustekinumab. The patient presents to an outpatient infusion/medication clinic, specialty dermatology clinic, or gastroenterology clinic for administration. The clinical workflow includes verification of diagnosis and prior authorization, pre-administration screening (infection symptoms, tuberculosis screening review, current medications, pregnancy status), medication reconciliation, patient education about expected effects and adverse events, preparation of the appropriate dose (drawn or prefilled syringe, based on weight and indication), subcutaneous injection by a licensed clinician or documented self-administration when appropriate, and observation for immediate adverse reactions (typically 15–30 minutes). Documentation includes the drug name and HCPCS code J3357, lot number, expiration date, units administered, site of administration, any applicable modifier (for example JW for discarded drug), patient vitals, and consent or refusal. Billing may be submitted to payors such as Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, BUCA, and Medicare according to their coverage and prior authorization policies.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |